Breaking Finance News

Oxford Immunotec Global PLC (NASDAQ:OXFD) has been upgraded to Hold in a statement by TheStreet earlier today.

TheStreet has upgraded Oxford Immunotec Global PLC (NASDAQ:OXFD) to Hold in a statement released on Friday September 30, 2016.

On Tuesday June 23, 2015, BTIG Research released a statement on Oxford Immunotec Global PLC (NASDAQ:OXFD) upped the target price from $0.00 to $21.00 that suggested an upside of 0.47%.

Having a price of $12.83, Oxford Immunotec Global PLC (NASDAQ:OXFD) traded 2.15% higher on the day. With the last close up 29.33% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. OXFD has recorded a 50-day average of $11.11 and a two hundred day average of $9.92. Trade Volume was down over the average, with 42,680 shares of OXFD changing hands under the typical 66,252

Recent Performance Chart

Oxford Immunotec Global PLC (NASDAQ:OXFD)

Oxford Immunotec Global PLC has with a one year low of $7.73 and a one year high of $14.25 and has a market capitalization of $0.

General Company Details For Oxford Immunotec Global PLC (NASDAQ:OXFD)

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company's T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions. Its development activities are principally focused on approximately four areas: chronic infections; transplantation; autoimmune and inflammatory disease, and immune-oncology. The Company's autoimmune and inflammatory disease programs include its SpiroFind assay, targeting Lyme disease; GoutiFind, targeting gout, and Stratokine, targeting efficacy of biologic therapies. Its T-SPOT.TB test is used to test for Tuberculosis (TB) infection. Its T-SPOT.CMV assay is used to assess the strength of a patient's cellular immune response to cytomegalovirus (CMV), infection. It is also developing T-SPOT.PRT and T-SPOT.ICA.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.